Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The company earned $799 million during the quarter, compared to analyst estimates of $787.07 million. During the same quarter in the previous year, the firm earned $1.16 earnings per share. Alexion Pharmaceuticals’s revenue was up 19.9% on a year-over-year basis.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 7.06% during midday trading on Thursday, hitting $130.18. The stock had a trading volume of 1,746,125 shares. Alexion Pharmaceuticals has a 52-week low of $110.56 and a 52-week high of $193.45. The stock has a market cap of $29.19 billion, a PE ratio of 327.09 and a beta of 1.33. The company’s 50 day moving average price is $124.75 and its 200-day moving average price is $132.99.

Earnings History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Several research analysts have recently commented on the company. Credit Suisse Group AG raised Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a report on Tuesday, July 12th. They set an “outperform” rating and a $188.00 price objective for the company. Leerink Swann boosted their price objective on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the stock an “outperform” rating in a report on Monday, September 26th. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, September 22nd. Finally, Jefferies Group restated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company. Alexion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $176.10.

In other Alexion Pharmaceuticals news, CFO Vikas Sinha sold 277 shares of Alexion Pharmaceuticals stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $37,987.78. Following the completion of the sale, the chief financial officer now directly owns 178,463 shares of the company’s stock, valued at approximately $24,474,415.82. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Alvin S. Parven sold 15,000 shares of Alexion Pharmaceuticals stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $136.53, for a total value of $2,047,950.00. Following the sale, the director now directly owns 6,373 shares of the company’s stock, valued at $870,105.69. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

A number of large investors have recently modified their holdings of ALXN. Investors Capital Advisory Services raised its stake in shares of Alexion Pharmaceuticals by 0.7% in the second quarter. Investors Capital Advisory Services now owns 1,996 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 14 shares during the period. Navellier & Associates Inc raised its stake in shares of Alexion Pharmaceuticals by 0.5% in the second quarter. Navellier & Associates Inc now owns 3,477 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 17 shares during the period. Bremer Trust National Association raised its stake in shares of Alexion Pharmaceuticals by 0.5% in the third quarter. Bremer Trust National Association now owns 5,478 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 26 shares during the period. Mn Services Vermogensbeheer B.V. raised its stake in shares of Alexion Pharmaceuticals by 0.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 5,691 shares of the biopharmaceutical company’s stock worth $598,000 after buying an additional 43 shares during the period. Finally, MSI Financial Services Inc raised its stake in shares of Alexion Pharmaceuticals by 1.0% in the third quarter. MSI Financial Services Inc now owns 4,290 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 44 shares during the period. 96.36% of the stock is owned by institutional investors and hedge funds.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.